Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
51.3 USD | +2.09% | +5.02% | +7.03% |
May. 15 | HC Wainwright Adjusts Korro Bio's Price Target to $100 From $115, Keeps Buy Rating | MT |
May. 14 | Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer | MT |
Valuation
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Capitalization 1 | 383.3 | 475.7 | - | - |
Enterprise Value (EV) 1 | 383.3 | 475.7 | 475.7 | 475.7 |
P/E ratio | -0.9 x | -5.32 x | -5.44 x | -6.22 x |
Yield | - | - | - | - |
Capitalization / Revenue | - | - | - | - |
EV / Revenue | - | - | - | - |
EV / EBITDA | - | - | - | - |
EV / FCF | -5.1 x | -5.73 x | -5.17 x | - |
FCF Yield | -19.6% | -17.4% | -19.3% | - |
Price to Book | - | - | - | - |
Nbr of stocks (in thousands) | 7,997 | 9,273 | - | - |
Reference price 2 | 47.93 | 51.30 | 51.30 | 51.30 |
Announcement Date | 3/26/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA | - | - | - | - | - |
EBIT 1 | - | -84.53 | -86.3 | -95.42 | -101.8 |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -58.02 | -81.14 | -81.12 | -92.65 | -101.8 |
Net income 1 | -58.03 | -81.17 | -81.16 | -92.65 | -101.8 |
Net margin | - | - | - | - | - |
EPS 2 | - | -53.08 | -9.640 | -9.437 | -8.250 |
Free Cash Flow 1 | - | -75.12 | -83 | -92 | - |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 7/27/23 | 3/26/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | -26.89 | -21.45 | -20.91 | -21.28 | -21.91 | -22.5 | -23.12 |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -25.4 | -19.54 | -20.33 | -20.51 | -21.22 | -21.88 | -22.6 |
Net income 1 | -25.43 | -19.56 | -20.34 | -20.51 | -21.22 | -21.88 | -22.6 |
Net margin | - | - | - | - | - | - | - |
EPS 2 | -43.10 | -2.440 | -2.395 | -2.340 | -2.465 | -2.600 | -2.480 |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 3/26/24 | 5/14/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net Debt | - | - | - | - | - |
Net Cash position | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow 1 | - | -75.1 | -83 | -92 | - |
ROE (net income / shareholders' equity) | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets 1 | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - |
Capex 1 | - | 7.84 | 5 | 5 | - |
Capex / Sales | - | - | - | - | - |
Announcement Date | 7/27/23 | 3/26/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.03% | 476M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- KRRO Stock
- Financials Korro Bio, Inc.